Close Menu

The story has been updated to correct the spelling of Nicolas Arab's name, the sample types that can be used with Klaris' test, and the total amount the company has raised. We apologize for the errors. 

NEW YORK (360Dx) – With $3.75 million from its recently completed Series A financing round, Klaris Diagnostics aims to simplify antibiotic selection for drug-resistant infections with its phenotypic single-cell platform.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.